22-Oxo-tricosanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 22-Oxo-tricosanoic acid
• 英文别名: 22-oxotricosanoic acid
• 化学式: C₂₃H₄₄O₃
• 分子量: 368.6
• InChiKey: DWIGCHXTZQHDFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  26
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
  申请人：Madsen Peter

  公开号：US20110105720A1

  公开（公告）日：2011-05-05

  Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.

  具有对蛋白酶抵抗力的新型酰化胰岛素类似物可以通过肺部或口服有效地给予。胰岛素类似物包含B25H和A14E或A14H。
• PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES
  申请人：NOVO NORDISK A/S

  公开号：US20150210748A1

  公开（公告）日：2015-07-30

  Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.

  具有对蛋白酶抗性的新型酰化胰岛素类似物可以有效地通过肺部或口服给药。胰岛素类似物包含B25H和A14E或A14H。
• Protease stabilized, acylated insulin analogues
  申请人：Novo Nordisk A/S

  公开号：EP2910570B1

  公开（公告）日：2016-10-12
• Novel antibacterial agents
  申请人：Christensen G. Burton

  公开号：US20070154948A1

  公开（公告）日：2007-07-05

  This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.
• N-Terminally Modified Insulin Derivatives
  申请人：Novo Nordisk A/S

  公开号：US20140357838A1

  公开（公告）日：2014-12-04

  The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such.